Delfi Diagnostics reported that its cfDNA-based FirstLook Lung liquid biopsy assay drove roughly a three-fold increase in lung cancer screening rates in a cluster-randomized interventional FIRSTLUNG study presented at ATS. In nearly 3,000 patients behind on recommended screening across clinics in Colorado, Florida, and North Carolina, the test showed 80% sensitivity, 56% specificity, and a negative predictive value of 99.8%. The company said access to FirstLook Lung nearly tripled overall screening and increased low-dose CT screening by 1.5-fold compared with baseline patterns. Delfi also highlighted that cancers detected were frequently stage I, which may expand treatment options for patients. Delfi has submitted the results to a peer-reviewed journal, and the company modeled that modest uptake gains over five years could prevent slightly more than 3,000 deaths in a simulated US population of 15 million people behind on screening.